Verteporfin photodynamic therapy for neovascular age-related ...
Verteporfin photodynamic therapy for neovascular age-related ... Verteporfin photodynamic therapy for neovascular age-related ...
144 Appendix 1College of Ophthalmologists, which represents eye specialists,has set up a body of people to monitor the study while it isbeing carried out. This body includes eye specialists, publichealth specialists and a representative from the MacularDisease Society, an organisation which represents the interestsof patients with macular degeneration. This body will ensurethat patient confidentiality and health are not jeopardised in anyway.If you have any other questions about the cohort study pleasefeel free to speak with a member of the clinical team lookingafter you. A contact name and number is provided belowNamed contact: -------------------------------Telephone:---------------
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 6145Hospital /Institution Headed paperCONSENTI have read or have had read to me the aboveconcerning the treatment of Age Related MacularDegeneration using Visudyne in the UK PDT cohortstudy. All my questions have been answered and I amwilling to allow information on my eyesight and clinicalcondition to be made available to the researchersundertaking this work.I am / am not willing to complete the questionnaires inthe cohort study.I agree / do not agree to my GP being informed aboutmy participation in this study.______________ _____________ __________Date Name of Patient Signature______________ _____________ __________Date Name of Doctor Signature© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State for Health.
- Page 108 and 109: 94 Appendix 1And, if also collectin
- Page 110 and 111: 96 Appendix 1more patients in the v
- Page 112 and 113: 98 Appendix 12.4 Limitations of the
- Page 114 and 115: 100 Appendix 1Box 2 Key advantages
- Page 116 and 117: 102 Appendix 14. Study population4.
- Page 118 and 119: 104 Appendix 15. Recruitment to the
- Page 120 and 121: 106 Appendix 16. Background data co
- Page 122 and 123: 108 Appendix 1Table 1: Schedule of
- Page 124 and 125: 110 Appendix 1The Verteporfin Photo
- Page 126 and 127: 112 Appendix 1• Additional clinic
- Page 128 and 129: 114 Appendix 18. Recording adverse
- Page 130 and 131: 116 Appendix 1level of benefit from
- Page 132 and 133: 118 Appendix 1• comparison of num
- Page 134 and 135: 120 Appendix 110.6 Sub-group analys
- Page 136 and 137: 122 Appendix 112. Data issues12.1 D
- Page 138 and 139: 124 Appendix 113. Organisation13.1
- Page 140 and 141: 126 Appendix 114. References[1] Ref
- Page 142 and 143: 128 Appendix 1Barnes RM, Gee L, Tay
- Page 144 and 145: 130 Appendix 1Appendix 1: Classifyi
- Page 146 and 147: 132 Appendix 1Liverpool re-treatmen
- Page 148 and 149: 134 Appendix 1Service StructurePlea
- Page 150 and 151: 136 Appendix 1Has your photographer
- Page 152 and 153: 138 Appendix 1There are many differ
- Page 154 and 155: 140 Appendix 1testing on vision tes
- Page 156 and 157: 142 Appendix 1something to do with
- Page 160 and 161: 146 Appendix 1Appendix 5:Protocol f
- Page 162 and 163: 148 Appendix 16.2 Subjective Refrac
- Page 164 and 165: 150 Appendix 1• The patient shoul
- Page 166 and 167: 152 Appendix 1Appendix 6:Protocol f
- Page 168 and 169: 154 Appendix 18. It is customary to
- Page 170 and 171: 156 Appendix 1Early or Transit Phas
- Page 172 and 173: 158 Appendix 1
- Page 174 and 175: 160 Appendix 1---------------------
- Page 176 and 177: 162 Appendix 1---------------------
- Page 178 and 179: 164 Appendix 1---------------------
- Page 180 and 181: 166 Appendix 1Appendix 9:Site imple
- Page 182 and 183: 168 Appendix 1Option 2 - units inte
- Page 184 and 185: 170 Appendix 1Dos and Don’tsDosDo
- Page 186 and 187: 172 Appendix 1Resource use question
- Page 188 and 189: 174 Appendix 1Appendix 11: Recommen
- Page 190 and 191: 176 Appendix 1ADVERSE REACTION AND
- Page 192 and 193: 178 Appendix 1acute Trust; note tha
- Page 194 and 195: 180 Appendix 1Ophthalmologistrespon
- Page 197 and 198: DOI: 10.3310/hta16060Health Technol
- Page 199 and 200: DOI: 10.3310/hta16060Health Technol
- Page 201 and 202: DOI: 10.3310/hta16060Health Technol
- Page 203: DOI: 10.3310/hta16060Health Technol
- Page 206 and 207: 192 Appendix 3manufacturer’s pers
144 Appendix 1College of Ophthalmologists, which represents eye specialists,has set up a body of people to monitor the study while it isbeing carried out. This body includes eye specialists, publichealth specialists and a representative from the MacularDisease Society, an organisation which represents the interestsof patients with macular degeneration. This body will ensurethat patient confidentiality and health are not jeopardised in anyway.If you have any other questions about the cohort study pleasefeel free to speak with a member of the clinical team lookingafter you. A contact name and number is provided belowNamed contact: -------------------------------Telephone:---------------
Change language